These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38656186)

  • 21. Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy.
    Bue M; Sou T; Okkels ASL; Hanberg P; Thorsted A; Friberg LE; Andersson TL; Öbrink-Hansen K; Christensen S
    Int J Infect Dis; 2020 Mar; 92():133-140. PubMed ID: 31978581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between Extended Meropenem Regimen and Achievement of Aggressive PK/PD in Patients Receiving Continuous Renal Replacement Therapy for Septic AKI.
    Chihara S; Ishigo T; Kazuma S; Matsumoto K; Morita K; Masuda Y
    Antibiotics (Basel); 2024 Aug; 13(8):. PubMed ID: 39200055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy.
    Chaijamorn W; Rungkitwattanakul D; Pattharachayakul S; Singhan W; Charoensareerat T; Srisawat N
    J Crit Care; 2020 Dec; 60():285-289. PubMed ID: 32949895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients.
    Luque S; Benítez-Cano A; Larrañaga L; Sorlí L; Navarrete ME; Campillo N; Carazo J; Ramos I; Adalia R; Grau S
    Antibiotics (Basel); 2021 Jun; 10(6):. PubMed ID: 34204943
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
    Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
    J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
    Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
    J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic drug monitoring of meropenem and pharmacokinetic-pharmacodynamic target assessment in critically ill pediatric patients from a prospective observational study.
    Maimongkol P; Yonwises W; Anugulruengkitt S; Sophonphan J; Treyaprasert W; Wacharachaisurapol N
    Int J Infect Dis; 2022 Jul; 120():96-102. PubMed ID: 35489632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceftriaxone Pharmacokinetics and Pharmacodynamic Target Attainment for Three Pediatric Patients Receiving Continuous Kidney Replacement Therapy.
    Hambrick HR; Cervantes F; Dong M; Tang P; Arbough T; Vinks AA; Mizuno T; Goldstein SL; Kaplan J; Girdwood ST
    J Pediatr Pharmacol Ther; 2024 Apr; 29(2):180-187. PubMed ID: 38596427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
    Awissi DK; Beauchamp A; Hébert E; Lavigne V; Munoz DL; Lebrun G; Savoie M; Fagnan M; Amyot J; Tétreault N; Robitaille R; Varin F; Lavallée C; Pichette V; Leblanc M
    Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reappraisal of the Optimal Dose of Meropenem in Critically Ill Infants and Children: a Developmental Pharmacokinetic-Pharmacodynamic Analysis.
    Wang ZM; Chen XY; Bi J; Wang MY; Xu BP; Tang BH; Li C; Zhao W; Shen AD
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization of meropenem dosage in the critically ill population based on renal function.
    Crandon JL; Ariano RE; Zelenitsky SA; Nicasio AM; Kuti JL; Nicolau DP
    Intensive Care Med; 2011 Apr; 37(4):632-8. PubMed ID: 21136037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meropenem for the Pharmacological Treatment of Severe Infections in Critically Ill Pediatric Patients: Breakthrough Standard Treatment Strategies Based on PK/PD.
    He X; Liu X; Gong X; Wang L; Chen F
    Curr Drug Metab; 2023; 24(1):5-15. PubMed ID: 36974414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization.
    Cojutti PG; Gatti M; Rinaldi M; Tonetti T; Laici C; Mega C; Siniscalchi A; Giannella M; Viale P; Pea F
    Front Pharmacol; 2021; 12():781892. PubMed ID: 34955851
    [No Abstract]   [Full Text] [Related]  

  • 35. Population Pharmacokinetics/Pharmacodynamics and Clinical Outcomes of Meropenem in Critically Ill Patients.
    Boonpeng A; Jaruratanasirikul S; Jullangkoon M; Samaeng M; Wattanavijitkul T; Bhurayanontachai R; Pattharachayakul S
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0084522. PubMed ID: 36226944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial.
    Benítez-Cano A; Luque S; Sorlí L; Carazo J; Ramos I; Campillo N; Curull V; Sánchez-Font A; Vilaplana C; Horcajada JP; Adalia R; Bermejo S; Samsó E; Hope W; Grau S
    Crit Care; 2020 Feb; 24(1):55. PubMed ID: 32066497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing Meropenem in Highly Resistant Klebsiella pneumoniae Environments: Population Pharmacokinetics and Dosing Simulations in Critically Ill Patients.
    Truong AQ; Dao XC; Vu DH; Nguyen HA; Do THG; Tran NT; Tran NM; Vu NB; Pham HN; Bui VC; Trinh TA; Dang QT; Nguyen GB; Lipman J; Cotta MO; Roberts JA
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0032122. PubMed ID: 36197095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients.
    Mathew SK; Mathew BS; Neely MN; Naik GS; Prabha R; Jacob GG; K S; Fleming DH
    Ther Drug Monit; 2016 Oct; 38(5):593-9. PubMed ID: 27454665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
    Carlier M; Carrette S; Roberts JA; Stove V; Verstraete A; Hoste E; Depuydt P; Decruyenaere J; Lipman J; Wallis SC; De Waele JJ
    Crit Care; 2013 May; 17(3):R84. PubMed ID: 23642005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.